

Almirall and Kaken Pharmaceutical enter into a license and distribution agreement for European rights to the topical formulation of efinaconazole

- **Efinaconazole is a triazole antifungal compound indicated for the treatment of fungal infection of the nail, known as onychomycosis**
- **Almirall acquires exclusive rights for the development and commercialization of this topical antifungal in Europe**

BARCELONA, Spain. July 1, 2021 – Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health, and **Kaken Pharmaceutical (KKPCF)** announced today that the companies have entered into a **license and distribution agreement** in which Kaken Pharmaceutical grants Almirall the exclusive right for the development and commercialization of the topical formulation of efinaconazole in Europe.

This active principle, a triazole antifungal compound discovered by Kaken Pharmaceutical, is indicated for the treatment of onychomycosis, a fungal infection of the nail. Since it has low binding affinity with keratin, the main component of nails, it has superior nail-penetrating properties. Global prevalence of onychomycosis is estimated to be around 5.5%¹ and the condition is responsible for 50% of all consultations for nail disorders².

The product has been marketed in Japan since 2014 under the trade name of Clenafin[®]. It has also been launched in the United States, Canada, Korea, Taiwan, Hong Kong and Macau by Kaken Pharmaceutical's partner companies under the trade name of Jublia[®].

Under the agreement, Kaken Pharmaceutical receives an upfront cash payment and has the potential to receive milestone payments and royalties on the net sales of the product. Almirall plans to have a pre-submission meeting with regulatory authorities within the next year to prepare the approval of the product in Europe.

With the addition of this new product, Almirall strengthens its European medical dermatology portfolio and reinforces its commitment to patients and dermatologists by offering them novel therapeutic options that really make a difference in their lives.

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient's needs through science to improve their lives. Our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life". We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 77-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2020 were 814.5 million euros.

For more information, please visit almirall.com

About Kaken Pharmaceutical

Kaken Pharmaceutical Co., Ltd. (KAKEN) is a specialty pharmaceutical company in Japan with strong experience in developing and commercializing novel pharmaceuticals and medical devices in the fields of orthopedics and dermatology. KAKEN concentrates its R&D resources in areas such as the immune system, the nervous system, and infectious diseases. KAKEN's ongoing quest is to Bringing Smiles to Everyone. For this purpose, KAKEN strives to improve the quality of life of patients through the development and distribution of superior pharmaceuticals. For further information, visit <http://www.kaken.co.jp>.

Media contact:

Tinkle
Pilar Colomer
pcolomer@tinkle.es
Phone: (+34) 93 545 12 51

Investors' Relations contact

Almirall
Pablo Divasson del Fraile
pablo.divasson@almirall.com
Phone: (+34) 93 291 3087

Corporate Communications contact:

Almirall
Ester Riu
ester.riu@almirall.com
Phone: (+34) 671 580 438

Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.

If you wish to unsubscribe from any Almirall Corporate communication, click [here](#).

In accordance with the General Data Protection Regulation and the applicable local regulations, we inform you that your personal data is processed by Almirall S.A. with registered address at Ronda del General Mitre 151, -08022-, Barcelona (Spain), acting as Controller in line with the purposes indicated in our Privacy Policy. For further information, you may consult it at <https://www.almirall.com/privacy-policy> or contact our Data Protection Officer at the e-mail address: dpo.global@almirall.com. PRNewswire is the Agency that licenses your personal data according to their privacy policy <https://gdpr.cision.com/gdpr>. At any time you can exercise your rights of access, rectification, deletion, objection, portability as well as the limitation of the processing of your data in the terms provided in the current regulations on Data Protection, by addressing the corresponding written request to our postal address (Ronda General Mitre, 151, 08022 Barcelona, Spain). The request to exercise any of your rights must be accompanied by a copy of an official document that identifies you (ID, driver's license or passport). Finally, we inform you that you can contact the Spanish Data Protection Agency and any other competent public bodies for any claim arising from the processing of your personal data.

1. Gupta AK, Mays RR, Versteeg SG, et al. Global perspectives for the management of onychomycosis. *Int J Dermatol*. 2018.
2. Piraccini, B.M, Alessandrini, A. Onychomycosis: A Review. *J Fungi [Internet]*. 2015 Jun;1(1): 30-43. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770011/>. doi: 10.3390/jof1010030.